公开(公告)号：EP3070475B1

公开(公告)日：2020-02-19

申请号：EP16161135.5

申请日：2016-03-18

申请人： Kellner, Karl-Heinz

发明人： Kellner, Karl-Heinz

IPC分类号： G01N33/68

公开(公告)号：EP3070475A3

公开(公告)日：2016-12-14

申请号：EP16161135.5

申请日：2016-03-18

申请人： Kellner, Karl-Heinz

发明人： Kellner, Karl-Heinz

IPC分类号： G01N33/68

摘要： Method of in-vitro diagnosis of an increased risk for contrast-induced nephropathy (CIN) in a patient even before the patient is subjected to coronary angiography or any examination requiring the administration of a contrast medium. The disclosure comprises an immunological determination of the kynurenine concentration in serum and informs the physician of the risks of a MARE (major adverse renal event) or MACE (major cardiovascular event).

公开(公告)号：EP3070475A2

公开(公告)日：2016-09-21

申请号：EP16161135.5

申请日：2016-03-18

申请人： Kellner, Karl-Heinz

发明人： Kellner, Karl-Heinz

IPC分类号： G01N33/68

摘要： Method of in-vitro diagnosis of an increased risk for contrast-induced nephropathy (CIN) in a patient even before the patient is subjected to coronary angiography or any examination requiring the administration of a contrast medium. The disclosure comprises an immunological determination of the kynurenine concentration in serum and informs the physician of the risks of a MARE (major adverse renal event) or MACE (major cardiovascular event).

摘要翻译： 甚至在患者进行冠状动脉血管造影术或需要施用造影剂的任何检查之前，体外诊断患者中造影剂引起的肾病（CIN）风险增加的方法。 本公开内容包括免疫测定血清中的犬尿苷浓度，并告知医师MARE（主要不良肾事件）或MACE（主要心血管事件）的风险。

公开(公告)号：EP2612147B1

公开(公告)日：2016-03-30

申请号：EP11797208.3

申请日：2011-11-11

申请人： Kellner, Karl-Heinz

发明人： Kellner, Karl-Heinz

IPC分类号： G01N33/531 ,  G01N33/68 ,  C07H19/00

CPC分类号： G01N33/6812 ,  G01N33/531 ,  G01N33/6854

公开(公告)号：EP2612147A1

公开(公告)日：2013-07-10

申请号：EP11797208.3

申请日：2011-11-11

申请人： Kellner, Karl-Heinz

发明人： Kellner, Karl-Heinz

IPC分类号： G01N33/531 ,  G01N33/68 ,  C07H19/00

CPC分类号： G01N33/6812 ,  G01N33/531 ,  G01N33/6854

摘要： The invention relates to derivatizing agents for biogenic amines in order to produce aminated haptenes which provide antibodies after coupling to a support, said antibodies being capable of binding the aminated haptene with a higher affinity. The invention relates to various competing immunoassays using said antibodies for determining biogenic amines in bodily fluids. The derivatizing agent contains groups which can potentially form Pi adducts with amino acids of the CDR of the antibody. The groups are in close proximity to the reactive group that can react with the amine radical of the biogenic amine. Preferred examples of the derivatizing agent are compounds of formulae (III) and (IV).

摘要翻译： 本发明涉及用于生物胺的衍生剂，以产生胺化的半抗原，其在与载体偶联后提供抗体，所述抗体能够以更高的亲和力结合胺化的半抗原。 本发明涉及使用所述抗体测定体液中生物胺的各种竞争性免疫测定。 衍生剂含有可能与抗体的CDR的氨基酸形成P 1加合物的基团。 这些基团非常接近可与生物胺的胺基反应的反应性基团。 衍生剂的优选实例是式（III）和（IV）的化合物。